灯盏花素缓释片在Beagle犬体内相对生物利用度的研究  

The relative bioavailability of Breviscapine sustained-release tablets in Beagle dogs

作　　者：杨强[1] 杨俊毅[1] 李思成 张铃敏[1] 

机构地区：[1]四川大学华西药学院,四川成都610041 [2]成都一平医药科技发展有限公司,四川成都610045

出　　处：《华西药学杂志》2004年第3期175-178,共4页West China Journal of Pharmaceutical Sciences

摘　　要：目的　探讨灯盏花素缓释片在动物体内的药物动力学规律 ,并进行相对生物利用度研究。方法　采用双周期交叉试验设计 ,对Beagle犬单剂量顿服灯盏花素缓释片和参比制剂的动力学参数进行比较。结果　采用尿药法进行数据处理 ,参比制剂与供试制剂的尿药总排泄量 (Xu)分别为 375 92 5± 4 7 2 3μg和 394 5 92± 32 84 μg ;生物半衰期 (t1/2 )分别为 7 197± 0 5 91h和 12 6 2± 1 2 0 7h。结论　以吸收总量为指标 ,灯盏花素缓释片与参比制剂相比是生物等效制剂 ,并具有缓释特征。OBJECTIVE To investigate the pharmacokinetics and the relative bioavailability of Breviscapine Sustained-release tablets in animals.METHODS The cross-over design(two periods)was employed.The pharmacokinetics parameters were compared after Beagle dogs were administrated a single dose of the oral Breviscapine Sustained-release tablets and the reference preparation.RESULTS The experimental data were caculated by uring-drug methods.Xu of the reference and the test preparations were 375.925±47.23 μg and 394.592±32.84 μg respechvely.The t 1/2 were 7.197±0.591 h and 12.62±1.207 h,respectively.CONCLUSION Compared with the reference preparation,Breviscapine Sustained-release tablets have the characteristic of sustained-release and are bioequivalent when the tolal absorptivity is taken as the index.

关 键 词：灯盏花素缓释片 BEAGLE犬 生物利用度 药物动力学 尿药法 

分 类 号：R969.1[医药卫生—药理学] R-332[医药卫生—药学]